Data

Medication Elimination

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Drug Class Percent of Prescriptions Eliminated
Sulfonylureas 100.0%
SGLT-2 91.3%
Thiazolidinedione 80.0%
DPP-4 54.8%
Insulin 47.6%
GLP-1 28.6%
Metformin 18.6%

A1c Reduction

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

  Baseline 10 weeks 1 year
Virta 7.5 6.4 6.2
Usual Care 7.7   7.9

Weight Reduction

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Treatment Weight loss at 12 months
Virta 12%

Retention

Bar chart comparing retention at one year: Virta (90%), Diabetes Medication Adherence (48%), Weight Loss Programs (13%)

Virta Health Registry for Remote Care of Chronic Conditions. Health and economic outcomes as of March 2019

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821

Martin CK, Talamini L, Johnson A, Hymel AM, Khavjou O. Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership. Int J Obes (Lond). 2010;34(4):742–750. doi:10.1038/ijo.2009.276

Treatment Retention
Virta 90%
Diabetes Medication Adherence 48%
Weight Loss Programs 13%

Rx Reduction

Line chart showing Rx Reduction over 2 years

Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial. Frontiers in Endocrinology. 2019; 10:348. DOI: 10.3389/fendo.2019.00348

Time in Clinic Diabetes-specific prescription use compared to baseline (%)
Baseline 100
10 weeks 42.5
6 months 41.9
1 year 41.9
2 years 40.2

Type 2 Diabetes

Bar charts showing comparison of Virta to Usual Care: Type 2 diabetes medications

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Hemoglobin A1c -17.24 2.62
Fasting glucose (mg·dL-1) -21.83 7.23
Insulin, all (mU·mL-1) -36.83 2.95
HOMA-IR (insulin derived), excluding exogenous insulin users -54.87 16.06
Any diabetes medication, excluding metformin (%) -47.81 8.98

Obesity

Bar chart showing comparison of Virta to Usual Care: Weight loss

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Weight-clinic (kg) -11.84 -0.15

Atherogenic Dyslipidemia

Bar charts showing comparison of Virta to Usual Care: Atherogenic Dyslipidemia

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Triglycerides (mg·dL-1) -24.39 10.19
HDL-C (mg·dL-1) 18.10 -2.83

Hypertension

Bar charts showing comparison of Virta to Usual Care: Hypertension

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Systolic blood pressure (mmHg) -4.82 -0.69
Diastolic blood pressure (mmHg) -4.28 -1.10
Any blood pressure medication (%) -17.01 15.72

Inflammation

Bar charts showing comparison of Virta to Usual Care: Inflammation

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
hsC-reactive protein (mg·L-1) -39.34 14.77
WBC (k·mm-3) -9.10 -0.74

Safety

Bar charts showing comparison of Virta to Usual Care: Safety measures

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Anion gap (mmol·L-1) 4.24 11.83
Uric acid (mg·dL-1) 0.68 -3.56
Serum creatinine (mg·dL-1) -4.55 -2.20
ALT (µkat·L-1) -29.82 2.02
AST (µkat·L-1) -20.61 3.01

Cardiovascular Risk Markers

Bar charts showing comparison of Virta to Usual Care: Cardiovascular risk markers

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
10-year ASCVD risk -11.93 11.21
Total LDL-P (nmol·L-1) -4.89 -4.41
Small LDL-P (nmol·L-1) -20.76 2.53
LDL-C (mg·dL-1) 9.62 -10.91
ApoB (mg·dL-1) -1.62 0.25
ApoB/ApoA1 ratio -9.46 1.37

We use cookies on our site to give you the best experience possible. By continuing to browse the site, you agree to this use. For more information on how we use cookies, see our Privacy Policy.

Continue